The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dose optimization for MORAb-202, an antibody-drug conjugate (ADC) highly selective for folate receptor-alpha (FRα), using population pharmacokinetic (PPK) and exposure-response (E-R) efficacy and safety analyses.
 
Seiichi Hayato
Employment - Eisai
 
Lora Hamuro
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Maiko Nomoto
Employment - Eisai
 
Shin Nishio
No Relationships to Disclose
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Mayu Yunokawa
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Merck; MSD; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); Merck (Inst); MSD (Inst); NanoCarrier (Inst); Takeda (Inst)
 
Koji Matsumoto
Honoraria - Chugai Pharma; Kaken Pharmaceutical; Kyowa Kirin; Lilly; MSD; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); ICON Clinical Research (Inst); ICON Clinical Research (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Kazuhiro Takehara
Honoraria - Abbvie; AstraZeneca; Chugai Pharma; Eisai; Fuji Pharma; Mochida Pharmaceutical Co. Ltd.; MSD; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma
 
Kosei Hasegawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; MSD K.K; Takeda
Consulting or Advisory Role - Kaken Pharmaceutical; MSD K.K
Research Funding - Daiichi Sankyo; Merck; Ono Pharmaceutical
 
Yasuyuki Hirashima
Speakers' Bureau - AstraZeneca; Chugai Pharma; MSD; Takeda
 
Hidenori Kato
No Relationships to Disclose
 
Toshio Shimizu
Consulting or Advisory Role - Abbvie; Daiichi Sankyo; Takeda
Speakers' Bureau - Chugai Pharma; Lilly
Research Funding - 3D Medicines (Inst); Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chordia Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); SymBio Pharmaceuticals (Inst); Takeda/Millennium (Inst)
Travel, Accommodations, Expenses - Takeda
 
Hiroki Ikezawa
Employment - Eisai
 
Yohei Otake
Employment - Eisai
 
Takuma Miura
Employment - Eisai
 
Yue Zhao
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Li Zhu
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Trixia Camacho
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Calin Dan Dumitru
Employment - Eisai
Stock and Other Ownership Interests - Eisai
 
Sanae Yasuda
Employment - Eisai